A Merck executive says the firm's Gardasil vaccine to protect against cervical cancer may have uses against a broader range of cancer-causing strains of human papillomavirus that aren't directly targeted by the vaccine. A Merck vice president said the firm is researching whether the vaccine also could prevent precancerous lesions caused by HPV strains.

Related Summaries